1,2,7-三甲基苯并咪唑 | 73902-56-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,2,7-三甲基苯并咪唑
• 英文名称: 1,2,7-trimethylbenzimidazole
• 英文别名: 1,2,7-trimethyl-1H-benzoimidazole；1,2,7-trimethyl-1H-benzimidazole；1,2,7-Trimethyl-1H-benzimidazol；1,2,7-Trimethylbenzimidazol；1,2,7-Trimethyl-1H-benzo[d]imidazole
• CAS: 73902-56-4
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: XIGAKKPZGANVMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-溴-3-甲基苯胺 在 四(三苯基膦)钯 potassium carbonate 、 三乙胺 、 sodium t-butanolate 、 三氯氧磷 作用下， 以 甲苯 为溶剂， 反应 36.0h， 生成 1,2,7-三甲基苯并咪唑
  参考文献：
  名称：

  An intramolecular palladium-catalysed aryl amination reaction to produce benzimidazoles

  摘要：

  A novel synthesis of benzimidazoles by a palladium-catalysed intramolecular N-arylation reaction from (o-bromophenyl)amidine precursors is described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(02)00132-6

文献信息

• [EN] SOMATOSTATIN MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE SOMATOSTATINE ET LEURS UTILISATIONS
  申请人：CRINETICS PHARMACEUTICALS INC

  公开号：WO2019157458A1

  公开（公告）日：2019-08-15

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些能够调节生长抑素的化合物，制备这些化合物的方法，包括这些化合物的药物组合物和药物，在治疗需要调节生长抑素活性的疾病、病症或疾病中使用这些化合物的方法。
• An Improved Procedure for the Synthesis of Benzimidazoles, Using Palladium-Catalyzed Aryl-Amination Chemistry
  作者：Christopher T. Brain、James T. Steer

  DOI：10.1021/jo034824l

  日期：2003.8.1

  New, improved conditions have been developed and optimized for the synthesis of benzimidazoles by intramolecular palladium-catalyzed aryl-amination chemistry. This methodology, combined with a "catch and release" purification strategy, has led to a range of these heterocycles being prepared rapidly and in excellent yield.

  为通过分子内钯催化的芳基胺化化学合成苯并咪唑开发了新的，改进的条件，并对其进行了优化。这种方法与“捕获和释放”纯化策略相结合，已导致快速制备了一系列这些杂环，并具有优异的收率。
• BENZIMIDAZOLE-PROLINE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150166527A1

  公开（公告）日：2015-06-18

  The present invention relates to compounds of the formula (I) wherein Ar 1 , R 1 , R 2 , R 3 , R 4a , R 4b and (R 5 ) n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的化合物，其中Ar1，R1，R2，R3，R4a，R4b和（R5）n如描述中所述，以及它们的制备，其药学上可接受的盐，以及它们作为药物的用途，包括含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠激素受体拮抗剂的用途。
• Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound
  申请人：Samsung Electronics Co., Ltd.

  公开号：US10797249B2

  公开（公告）日：2020-10-06

  An organometallic compound represented by Formula 1: wherein in Formula 1, groups and variables are the same as described in the specification.

  由式 1 表示的有机金属化合物： 其中，公式 1 中的组别和变量与说明书中描述的相同。
• Benzimidazole-proline derivatives
  申请人：IDORSIA PHARMACEUTICALS LTD

  公开号：US11040966B2

  公开（公告）日：2021-06-22

  The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.

  本发明涉及式 (II) 的化合物 其中 Ar1、R1、R2、R3、R4a、R4b 和 (R5)n 如描述中所述，涉及它们的制备、其药学上可接受的盐及其作为药物的用途、含有一种或多种式 (II) 化合物的药物组合物，特别是它们作为奥曲肽受体拮抗剂的用途。